QRL-101 is under clinical development by QurAlis and currently in Phase I for Epilepsy. According to GlobalData, Phase I drugs for Epilepsy have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how QRL-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
QRL-101 overview
QRA-101 is under development for the treatment of amyotrophic lateral sclerosis, epilepsy. The drug candidate acts by targeting voltage-gated potassium channel subunits Kv7.2 and Kv7.3. The drug candidates are developed based on stem cell technology platform and the Q-State optopatch platform. It is administered through oral route.
It was under development for the treatment of frontotemporal dementia (FTD).
QurAlis overview
QurAlis is a pharmaceutical company that carries out the business of discovering, developing and commercializing new therapies for the treatment of motor neuron disease such as amyotrophic lateral sclerosis (ALS). The company’s therapeutic programs include excitotoxicity in the motor system and restoration of autophagy pathways. QurAlis is also expanding its pipeline to other neurodegenerative diseases, such as frontotemporal-degeneration (FTD). It carries out platform which include QurAlis and FlexASO. QurAlis is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of QRL-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
